ADC Therapeutics Shares Positive Data from Recent Trials
ADC Therapeutics SA (NYSE: ADCT), a leader in antibody drug conjugates, has announced encouraging results from their ongoing LOTIS-7 clinical trial. This trial evaluates ZYNLONTA in combination with the bispecific antibody glofitamab, targeting patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
Key Findings of the LOTIS-7 Trial
Early reports indicate a remarkable best overall response rate (ORR) of 94% among patients treated with ZYNLONTA combined with glofitamab, showing promising outcomes, especially for patients who struggled with prior therapies. Notably, 72% of participants achieved a complete response (CR), further solidifying the efficacy of this treatment combination.
Overview of the Clinical Study
The LOTIS-7 Phase 1b trial is designed as a global multicenter study with both dose escalation and expansion components. It involves various arms to assess the safety and effectiveness of multiple dosing strategies. According to the November cutoff, 29 patients were treated within this study.
Efficacy Analysis Highlights
During the initial analysis, 18 patients who received doses of ZYNLONTA (120 µg/kg and 150 µg/kg) along with glofitamab were evaluated. Responses were striking, with all patients receiving 150 µg/kg reporting positive ORR, and the majority achieving CR.
Safety and Tolerability of the Treatment
The safety profile appears promising, with no dose-limiting toxicities (DLTs) reported and no occurrences of high-grade cytokine release syndrome (CRS) or neurotoxicity across the study. Adverse events reported were mainly low in severity and manageable, highlighting the potential for broad application of this combination therapy.
Implications for Future Treatment
ADC Therapeutics has expressed optimism about the findings, with expectations for the completion of the dose expansion phase by mid-next year. The company aims to work closely with regulatory authorities to navigate further clinical development based on expanding patient data and safety profiles.
About ADC Therapeutics
Located in Lausanne, ADC Therapeutics (NYSE: ADCT) is at the forefront of developing innovative antibody drug conjugate technology, transforming treatment strategies for serious cancers. Their flagship product, ZYNLONTA, has received accelerated approvals for treating specific lymphoma patients and is under continuous development.
Frequently Asked Questions
What is ADC Therapeutics known for?
ADC Therapeutics specializes in developing antibody drug conjugates, aiming to improve treatment options for cancer patients.
What did the clinical trial LOTIS-7 evaluate?
LOTIS-7 is evaluating the effectiveness and safety of ZYNLONTA combined with glofitamab in relapsed/refractory diffuse large B-cell lymphoma patients.
What were the initial findings of the trial?
The trial showed a 94% best overall response rate and a 72% complete response rate among evaluated patients, highlighting significant efficacy.
How does the treatment's safety profile appear?
The treatment has shown no significant toxicities or serious adverse events, indicating a favorable safety profile for both drugs.
What are the next steps for ADC Therapeutics?
ADC Therapeutics plans to finish enrolling patients for the expansion phase of the LOTIS-7 trial and will consult with regulatory authorities regarding future development.
